J Korean Surg Soc.  2007 Apr;72(4):270-275.

Clinical Features and Outcomes of Invasive Intraductal Papillary Mucinous Neoplasm: Comparison with Pancreatic Ductal Adenocarcinoma

• Paik KY
• Jung JC
• Heo JS
• Choi SH
• Choi DW
• Kim YI

Abstract

PURPOSE: Histologically, IPMN (intraductal papillary mucinous neoplasm) includes various grades of lesion, from hyperplasia and adenoma to adenocarcinoma. The prognosis is different for each histological grade. The malignant IPMN contain in-situ and invasive carcinoma. The purpose of this study was to investigate the clinicopathologic features and outcome of invasive IPMN.
METHODS
18 patients with invasive IPMN underwent surgical treatment between October 1994 and December 2005 at Samsung Medical Center. The clinical, biochemical and pathologic features were retrospectively analyzed. Survival and the clinicopathologic features were compared between invasive IPMN and PDAC of the well differentiated type (wd, n=27) and carcinoma in-situ (CIS, n=10).
RESULTS
The preoperative CA19-9 level and total bilirubin level of invasive IPMN patients was statistically higher than those of the CIS patients. The tumor size of invasive IPMN was larger than that of PDAC (wd) (P=0.038). The median survival of patients with invasive IPMN was 31.0 month. The 5-year survival rates of patients with PDAC (wd) and invasive IPMN were 35.5% and 41.7%, respectively (P= 0.237).
CONCLUSION
there were no differences for invasive IPMN and PDAC (wd) except for tumor size. The survival in patients with surgical resected invasive IPMN was similar to that of the patients with surgical resected PDAC (wd).

Keyword

Invasive; Intraductal papillary mucinous neoplasm (IPMN); Carcinoma in-situ (CIS); Pancreatic ductal adenocarcinoma; Well differentiated

MeSH Terms

Adenocarcinoma*
Adenoma
Bilirubin
Humans
Hyperplasia
Mucins*
Pancreatic Ducts*
Prognosis
Retrospective Studies
Survival Rate
Bilirubin
Mucins